Scinai investor reports 16.61% ADS ownership
Scinai Immunotherapeutics Ltd. disclosed that investor Daniel E. Stone and RK Stone Miami, LLC together beneficially own 584,534 American Depositary Shares (ADSs), representing 16.61% of the ADS class.
Rhea-AI Filing Summary
Scinai Immunotherapeutics Ltd. disclosed that investor Daniel E. Stone and RK Stone Miami, LLC together beneficially own 584,534 American Depositary Shares (ADSs), representing 16.61% of the ADS class. Each ADS represents 4,000 ordinary shares. Stone individually reports 346,667 ADSs with sole voting and dispositive power, while RK Stone Miami, LLC reports 237,867 ADSs with sole voting and dispositive power.
The filing explains that RK Stone Miami, LLC holds ADSs and pre-funded warrants that cannot be exercised if this would raise its beneficial ownership, together with affiliates and certain other persons, above 9.99% of the issuer’s ordinary shares. The reporting persons certify the securities are not held for the purpose of changing or influencing control of the company.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Scinai Immunotherapeutics (SCNI) does Daniel E. Stone report?
How many Scinai Immunotherapeutics ADSs does RK Stone Miami, LLC hold?
What percentage of Scinai Immunotherapeutics (SCNI) does 584,534 ADSs represent?
Are RK Stone Miami’s pre-funded warrants in SCNI subject to an ownership cap?
Did RK Stone Miami, LLC exercise any Scinai Immunotherapeutics warrants in 2025?
Are the SCNI securities held by Daniel E. Stone intended to influence control of the company?
AI-generated analysis. How Rhea-AI works. Not financial advice.